Mechanisms of the release of anterogradely transported neurotrophin-3 from axon terminals by Wang, XiaoXia et al.
Mechanisms of the Release of Anterogradely Transported
Neurotrophin-3 from Axon Terminals
XiaoXia Wang,1 Rafal Butowt,1 Michael R. Vasko,2 and Christopher S. von Bartheld1
1Department of Physiology and Cell Biology, University of Nevada School of Medicine, Reno, Nevada 89557, and
2Department of Pharmacology and Toxicology, University of Indiana School of Medicine, Indianapolis, Indiana
46202-5120
Neurotrophins have profound effects on synaptic function and
structure. They can be derived from presynaptic, as well as
postsynaptic, sites. To date, it has not been possible to mea-
sure the release of neurotrophins from axon terminals in intact
tissue. We implemented a novel, extremely sensitive assay for
the release and transfer of anterogradely transported
neurotrophin-3 (NT-3) from a presynaptic to a postsynaptic
location that uses synaptosomal fractionation after introduction
of radiolabeled NT-3 into the retinotectal projection of chick
embryos. Release of the anterogradely transported NT-3 in
intact tissue was assessed by measuring the amount remaining
in synaptosomal preparations after treatment of whole tecta
with pharmacological agents. Use of this assay reveals that
release of NT-3 from axon terminals is increased by depolariza-
tion, calcium influx via N-type calcium channels, and cAMP
analogs, and release is most profoundly increased by excitation
with kainic acid or mobilization of calcium from intracellular
stores. NT-3 release depends on extracellular sodium, CaM
kinase II activity, and requires intact microtubules and micro-
filaments. Dantrolene inhibits the high potassium-induced re-
lease of NT-3, indicating that release of calcium from intracel-
lular stores is required. Tetanus toxin also inhibits NT-3 release,
suggesting that intact synaptobrevin or synaptobrevin-like mol-
ecules are required for exocytosis. Ultrastructural autoradi-
ography and immunolabel indicate that NT-3 is packaged in
presumptive large dense-core vesicles. These data show that
release of NT-3 from axon terminals depends on multiple reg-
ulatory proteins and ions, including the mobilization of local
calcium. The data provide insight in the mechanisms of antero-
grade neurotrophins as synaptic modulators.
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Neurotrophins are important regulators of neuronal differentia-
tion and synaptic plasticity (Lohof et al., 1993; Snider, 1994; Kang
and Schuman, 1995; Thoenen, 1995; McAllister et al., 1999; Poo,
2001). Traditionally, neurotrophins were believed to be derived
by retrograde axonal transport from target cells, but recent stud-
ies revealed that neurotrophins are also transported antero-
gradely along axons (von Bartheld et al., 1996; Zhou and Rush,
1996; Altar et al., 1997; Conner et al., 1997; Heymach and Barres,
1997; Smith et al., 1997; Yan et al., 1997; Fawcett et al., 2000; von
Bartheld and Butowt, 2000) and may act as extremely potent
excitatory neurotransmitters (Kafitz et al., 1999). Anterograde
signals provide trophic support from afferents (Linden, 1994; von
Bartheld et al., 1996; Altar et al., 1997), may mediate fast, local
effects at synaptic sites (Lohof et al., 1993; Kang and Schuman,
1995; Thoenen, 1995; Kafitz et al., 1999; Poo, 2001), and regulate
dendritic growth, neuronal cytoarchitecture, and phenotypes (Al-
tar et al., 1997; McAllister et al., 1999; Fawcett et al., 2000).
Neurotrophin 3 (NT-3) enhances synaptic transmission in neu-
romuscular junctions (Lohof et al., 1993) and the brain (Kim et
al., 1994), alters short-term and long-term plasticity (Kang and
Schuman, 1995; Kokaia et al., 1998), and modifies the morphol-
ogy of cerebellar and cortical neurons (Lindholm et al., 1993;
McAllister et al., 1999). In the retinotectal system, endogenous
and exogenous NT-3 are moved by anterograde axonal transport
(von Bartheld and Butowt, 2000), and exogenous NT-3 is released
from retinotectal terminals and taken up by tectal dendrites,
promoting the survival of postsynaptic neurons (von Bartheld et
al., 1996). Release mechanisms are crucial for an understanding
of the action of neurotrophins (Lo, 1995; Thoenen, 1995; Fawcett
et al., 1997; Aloyz et al., 1999; Berninger and Poo, 1999; Schinder
and Poo, 2000), but mechanisms of the release of anterogradely
transported neurotrophins are completely unknown.
Neuropeptides are released by a variety of mechanisms, pre-
sumably by packaging into different types of vesicles that are
released by different mechanisms (Bartfai et al., 1988; Hille et al.,
1999; Kasai, 1999). Therefore, release mechanisms of neurotro-
phins cannot be predicted on the basis of what is known for other
neuropeptides. The role of anterogradely transported neurotro-
phins has been particularly difficult to assess because of the
absence of an assay that localizes the trophic factors within
synapses and is sufficiently sensitive to measure the excessively
small amounts released from axon terminals.
We developed a technique that allows us to measure the release
and transynaptic transfer of picomolar amounts of anterogradely
transported NT-3. A novel combination of autoradiographic, bio-
chemical, and experimental pharmacological techniques in an in
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vivo model system revealed which molecules and events regulate
the release of anterogradely transported NT-3 from axon termi-
nals. This technology will define the molecular mechanisms reg-
ulating neurotrophin release and help to better understand the
role of neurotrophins in neurotransmission and synaptic
plasticity.
Parts of this work have been published previously in abstract
form (Wang et al., 1999).
MATERIALS AND METHODS
Sources of materials
4-Aminopyridine (4-AP), cadmium chloride, colchicine, cytochalasin D,
cytochrome c, kainic acid, KN-93, strophanthidin, tetrodotoxin (TTX),
and thapsigargin were from Sigma (St. Louis, MO). 8-Br-cAMP, dan-
trolene, and forskolin were from ICN Biomedicals (Cleveland, OH).
BAPTA, BAPTA AM, -conotoxin-GVIA, KN-92, tetanus toxin, and
tetanus toxin C fragment were from Calbiochem (La Jolla, CA). Nerve
growth factor (NGF) was from Mark Bothwell (Seattle, WA) or Alomone
Labs (Jerusalem, Israel). Brain-derived neurotrophic factor (BDNF) and
NT-3 were from Regeneron (Tarrytown, NY). NT-3 antibody was from
Robert Rush (Adelaide, Australia). Calcium electrodes and calibration
buffers were from World Precision Instruments (Sarasota, FL). Fertilized
chicken eggs were from California Golden Eggs (Sacramento, CA). A
total of 3800 chicken eggs were used in this study; all embryos were
staged (Hamburger and Hamilton, 1951). Protocols were approved by the
local animal care committee, and surgical procedures were done after
anesthesia with sodium pentobarbital (Nembutal; 5 mg/embryo).
Injection of 125I-labeled proteins, trafficking, and release
Neurotrophins, cytochrome c, and tetanus toxin were radio-iodinated
with lactoperoxidase (von Bartheld, 2001), and substance P (SP) was
iodinated with the Bolton-Hunter reagent (NEN Life Sciences, Boston,
MA). Incorporation for NT-3 was 90–95%, and specific activity was
90–150 cpm/pg. Specific activities for NGF were 75–189 cpm/pg, for
cytochrome c were 36–72 cpm/pg, for tetanus toxin were 40–61 cpm/pg,
and for substance P were 18 cpm/pg. Fertilized chicken eggs were
incubated at 37°C. Embryos were windowed on embryonic day 15 (E15)
to E16, injected with 40–80 ng of 125I-labeled NT-3 in the eye in ovo on
E16–E17 (von Bartheld et al., 1996), and were perfused intracardially 20
hr later (at E17–E18) with ice-cold nondepolarizing buffer [low K
Krebs’ buffer (in mM): 134 NaCl, 5 KCl, 1 MgSO4  7 H2O, 1.25 KH2PO4,
2.0 CaCl2  2 H2O, 16 NaHCO3, and 10 glucose, pH 7.5 (after gassing
with 95% O2, 5%CO2)] to remove radioactivity that had leaked into
systemic circulation. The perfusion was also used to deliver pharmaco-
logical agents directly to the brain and to improve penetration. The
tectum was removed and placed in cold low K buffer, and its radioac-
tivity was counted in a gamma counter. Only tecta containing6000 cpm
(n  694) were used for subsequent release experiments, because such
tecta typically generated 200 cpm in synaptosomes and we found that
200 cpm were necessary to reliably quantify synaptosomal peaks. Each
dissected tectum was incubated in 3 ml of oxygenated low K buffer (6
mM K) or oxygenated high K buffer (56 mM K) (in mM: 84 NaCl, 55
KCl, 1 MgSO4  7 H2O, 1.25 KH2PO4, 2 CaCl2  2 H2O, 16 NaHCO3, and
10 glucose) at room temperature with or without experimental drugs for
60 min, unless indicated otherwise. Maximal transport capacity in the
retinotectal projection was tested by injection of 2–400 ng (0.5–30 
10 6 cpm in the eye at the time the animal was killed) and gamma-
counting of tecta after 20 hr. The amount of injected 125I-labeled NT-3
in the eye and the amount of anterogradely transported NT-3 in the
tectum was quantified; in addition, the amount of the radioactivity in the
synaptosomal peaks was taken as a measure for the amount and percent-
age of 125I-labeled NT-3 within the presynaptic terminals [excluding the
amount in the general membrane fraction containing the bulk of tectal
radioactivity: axons and dendrites (von Bartheld et al., 1996)].
Synaptosome preparation, data collection, and analysis
Synaptosomes were prepared to measure how much 125I-labeled NT-3
remained in presynaptic terminals. The protocol of Viglietti et al. (1977)
was used with slight modifications. The incubation buffer was replaced
with 5 ml of 0.32 M sucrose and 5 mM Tris, pH 7.4 (buffer B); tecta were
homogenized by trituration using a 1 ml syringe with a 20 G 1 1/2 gauge
needle. The suspension was centrifuged at 4°C for 10 min at 1500  g to
remove the crude nuclear fraction (P1). The pellet was washed two times
with 1 ml buffer B, and supernatants were removed and centrifuged at
17,000  g for 20 min to pellet the membrane fraction (P2). Pellet 1 and
supernatant (S2) were counted in a gamma counter. P2 was resuspended
in 10 ml of 0.32 M sucrose and loaded on a two-step discontinuous
ficoll–sucrose gradient in Quick-Seal tubes containing 15 ml of 13%
(w/v) ficoll in 0.32 M sucrose and overlaid with 15 ml of 7.5% (w/v) ficoll
in 0.32 M sucrose. The samples were centrifuged at 53,000  g for 90 min
at 4°C. The ultracentrifuge tubes were fractionated (50  0.8 ml frac-
tions), and each fraction was counted for 10 min in a gamma counter. The
radioactivity within the synaptosomal peak (defined by visual inspection
of the printed plots) was calculated as the ratio (divided by the total
radioactivity in the ultracentrifuge tube). The average ratio of the
synaptosomal peak in low K buffer was defined as 100% unless indi-
cated otherwise. The ratio of the synaptosomal peak/tube in the exper-
imental condition was divided by the average ratio of the synaptosomal
peak/tube in the low K buffer to calculate the percentage of NT-3
released from retinotectal terminals. Statistical significance was deter-
mined by unpaired Student’s t test or, for multiple comparisons, by
one-way ANOVA with Prism 2.01 software.
Proteins extracted from synaptosomal fractions derived from 125I-NT-
3-loaded tecta were examined by SDS-PAGE (15% gels). To examine
whether release of NT-3 from synaptosomal fractions (obtained from
125I-NT-3-loaded tecta) can be measured, synaptosomes were centri-
fuged and resuspended in either high or low K buffer, warmed to 37°C,
gassed for 60 min, and centrifuged again in either a microcentrifuge or
the ultracentrifuge. The pellets and supernatants were gamma counted
to determine release of 125I-NT-3 into the buffer.
Pharmacological manipulations of release
A total of 694 successful release experiments were performed to test
molecules potentially involved in release of NT-3. Control experiments
(low K or high K) were included in each experimental series of up to
eight centrifugation tubes for calibration of NT-3 release (“quality con-
trol”). For manipulation of release in vitro, the dissected tecta were
incubated with 3 ml of high K buffer containing one of the following
agents: 4-aminopyridine (1 mM), 8-Br-cAMP (50 M), cadmium chloride
(100 M), colchicine (175 M), cytochalasin D (0.2 M), dantrolene (50
M), forskolin (10 M), KN-93 (10 M), KN-92 (10 M), nifedipine (10
M), -conotoxin-GVIA (0.1 M), strophanthidin (500 M), tetrodo-
toxin (3 M), or thapsigargin (5 M). When drugs required dissolving in
DMSO or ethanol, control tecta were tested with identical vehicle
solution.
BAPTA. Buffers were prepared as described, except that CaCl2 was
replaced with MgCl2 at the same concentration. BAPTA AM (10 M) or
BAPTA (20 or 200 M) was added to the calcium-free buffers overnight
before use. Higher BAPTA concentrations were necessary because tecta
were a source of calcium that leaked into the incubation solution.
Calcium concentrations in the incubation buffer were measured with and
without tecta, and with normal calcium, or calcium-free buffers contain-
ing 20 M BAPTA, 200 M BAPTA, or 10 M BAPTA AM. Calcium
electrodes and calibration buffers were used as described previously
(Baudet et al., 1994).
N-Methyl-D-glucamine. N-Methyl-D-glucamine (NMG) was used to re-
place extracellular sodium in high K buffer (in mM: 100 NMG-HCl, 39
KCl, 1 MgSO4, 1.25 KH2PO4, 2 CaCl2, 16 KHCO3, and 10 glucose).
Chick embryos were perfused with high K buffer containing NMG,
dissected optic tecta were incubated in NMG buffer for 60 min, and the
tissue was further processed as described. Some NMG-treated tecta were
incubated in normal (Na-containing) high K buffer to determine
whether the NMG effect was reversible.
Tetanus toxin. Tetanus toxin (1–4 g) was injected into the eyes 1 d
before NT-3 injection to target the toxin by anterograde axonal transport
to the retinotectal nerve terminals. Whereas 4 g was lethal, 1–2 g was
tolerated. The tetanus toxin C fragment (responsible for trafficking of the
molecule) was radio-iodinated with lactoperoxidase to a specific activity
of 40–61 cpm/pg. Free iodide was removed by membrane centrifugation
(von Bartheld, 2001). Radiolabeled toxin C fragment (300 ng) was
injected into the eye of chick embryos, and the tecta were processed for
autoradiography to confirm that the toxin was transported anterogradely
by retinal ganglion cell (RGC) axons to the optic tectum. 125I-NT-3 was
coinjected with (cold) tetanus toxin to test whether the toxin interfered
with the normal anterograde transport of NT-3. The tecta, loaded with
tetanus toxin and 125I-NT-3, were treated with high K buffer and
processed as described.
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Control experiments
To determine whether NT-3 was released constitutively during the incu-
bation in low K buffer, the amount of NT-3 in retinotectal terminals
was compared between tecta processed immediately after killing, and
tecta were incubated for 60 min in oxygenated low K buffer. To
determine whether NT-3 or other neurotrophins or peptides bound to
terminals during the preparation of synaptosomes, the tectal homoge-
nates of normal (not injected) chick embryos were incubated with 0.1–0.3
ng/ml radio-iodinated NT-3, BDNF, NGF, SP, or cytochrome c and
subjected to ficoll–sucrose gradient centrifugation, and gamma counts
were plotted after fractionation. Some NT-3 preparations were incubated
with 500-fold excess cold NT-3 to determine specific, receptor-mediated
binding. Total protein content of synaptosomal peaks was measured by
UV absorption [Bio-Rad (Hercules, CA) standard protein assay].
Anterograde transport and release of other proteins
To compare the transport and release of NT-3 with that of other
proteins, we measured NGF, tetanus toxin C fragment, and cytochrome
c. These proteins were chosen because, unlike substance P, they can be
transported in the retinotectal system after intraocular injection. The
amount of radiolabeled protein injected in the eye was measured 20 hr
later to assess retention in the eye. The transport efficiency was measured
by comparing the amount in the eye at the time the animal was killed
with the amount contained in the contralateral tectum. By competing
with excess cold protein (20- to 50-fold), it was examined whether
anterograde transport was receptor mediated. Accumulation of the trans-
ported protein in retinotectal terminals was assessed by measuring the
radioactivity in the synaptosomal peak and comparing it with the total
radioactivity in the contralateral tectum.
In vivo release of NT-3
Kainic acid (8 l, 5 mM) was injected into the eye (estimated concentra-
tion in the eye, 0.625 mM) of 125I-NT-3 treated chick embryos 45 min
before dissection of the tecta. To determine whether the effect of the
kainic acid could be blocked by TTX, 5 l of TTX (100 M) or PBS (as
a control for the TTX application) was injected into the eyes, followed by
8 l of kainic acid (5 mM) 15 min later. The embryos were anesthetized
45 min later and perfused intracardially, and the tecta were processed as
described.
Release of substance P from tectal terminals
Radio-iodinated NT-3 was injected in the eye 20 hr before homogeniza-
tion of the tecta to identify the fractions containing the synaptosomal
peak. Tecta were treated with either low or high K buffer as described.
Fractions were counted in the gamma counter for 1 min. HCl was added
to 3 ml fractions containing synaptosomes, and samples were stored
immediately at 80°C. Samples of 500 l were analyzed by radioimmu-
noassay for the content of SP (Chen et al., 1996).
Vesicle purification
Tecta from E17 chick embryos loaded with 125I-labeled NT-3 were
dissected and homogenized at 4°C in 15 ml of buffered sucrose (4 mM
HEPES and 320 mM sucrose, adjusted to pH 7.3 with NaOH). Vesicles
were purified according to Huttner et al. (1983) and Han and Fischbach
(1999). After centrifugations, resuspended vesicles (6.7 ml) were loaded
on sucrose step gradients in 40 ml Quick-Seal centrifuge tubes, loaded
with 6.75 ml each of 50, 200, 400, 550, and 800 mM sucrose (from bottom
to top), and centrifuged at 24,500 rpm (42.1 rotor; 65,000  g) for 5 hr.
Fractions were collected, counted, and plotted as described for synapto-
some fractionations.
Electron microscopic autoradiography
and immunocytochemistry
Localization and quantification of anterogradely transported 125I-NT-3
in tectal tissue was performed by autoradiography as described previ-
ously (von Bartheld et al., 1996; von Bartheld, 2001). Five hundred thirty
silver grains from two E17 tecta with 125I-NT-3-loaded retinotectal
terminals were analyzed. Silver grains overlying presynaptic or postsyn-
aptic compartments were quantified, and the percentages of silver grains
were calculated. In addition, 87 silver grains within the stratum opticum
were analyzed for association with either endosomes or large dense-
cored vesicles (LDCVs) within axons. Synaptosomes from 125I-NT-3-
loaded tecta were fixed in 2.5% glutaraldehyde and centrifuged at
10,000  g at 4°C, embedded in Spurr, and sectioned at 80–90 nm.
Sections were coated with a monolayer of I lford L4 emulsion and
exposed for 8–10 weeks at 4°C. Developed sections were examined on a
Philips CM10 transmission electron microscope. The distribution of
silver grains was photographed, and 94 random silver grains were quan-
tified at a magnification of 15,000–20,000. For immunolabeling, tectal
tissue from E19–E20 embryos was fixed in 4% paraformaldehyde and
0.1% glutaraldehyde by intracardial perfusion. Standard pre-embedding
immunolabeling techniques were used. Tecta were sectioned with a
vibratome at 100–150 m. Endogenous peroxidase activity was quenched
by pretreatment with 3% H2O2. The sections were incubated for 24 hr at
4°C with 20 g/ml purified polyclonal antibodies to NT-3 (Zhou and
Rush, 1993) (courtesy of R. Rush, Flinders University, Adelaide, Aus-
tralia) and processed with the ABC kit (Vector Laboratories, Burlin-
game, CA). Sections were embedded in Spurr and thin sectioned at
80–90 nm. In control sections, the primary antibody was omitted.
RESULTS
Anterogradely transported 125I-NT-3 in tectal terminals
can be quantified
Injections of 40–80 ng of 125I-NT-3 in the eye resulted in a total
of 100 pg of 125I-NT-3 in the contralateral tectum. The synap-
tosomal peaks contained 5.94 0.36% (SEM; n 19) of the total
radioactivity measured in the contralateral tectum, equivalent to
15–20% of the radioactivity in the ultracentrifugation tube (Fig.
1A). Much of the radioactivity was found in the general mem-
brane fraction, containing 125I-NT-3 in retinal axons en route to
their terminals in the tectum (von Bartheld et al., 1996). There
was no radioactive peak in the synaptosomes from the ipsilateral
(control) tecta, indicating that accumulation of 125I-NT-3 in
tectal synaptosomes was not attributable to diffusion or uptake
after leakage into systemic circulation, and 125I-NT-3 arrived in
the tectum intact. The localization of anterogradely transported
125I-NT-3 in synaptosomes (after fractionation) was confirmed by
quantitative autoradiography at the ultrastructural level. Synap-
tosomes were identified in expected quality and quantity (60–
70% purity) (Viglietti et al., 1977), and 60% of silver grains
were located over clearly identified synaptosomes (Fig. 1B,C).
The identity of synaptosomal fractions was verified by increased
levels of synaptic vesicle protein (SV2) in Western blots (data not
shown). The association of radiolabeled NT-3 in synaptosomal
peaks with retinotectal terminals (rather than other tectal termi-
nals) can be concluded because of the fact that the highest level of
autoradiographic labeling in the tectum in situ occurs in the layer
known to contain the retinotectal terminals (von Bartheld et al.,
1996). To determine whether 125I-NT-3 in multivesicular bodies
(MVBs) of postsynaptic dendrites may contribute to the radio-
activity in the synaptosomal peak, silver grains over MVBs were
quantified. Only 2% of silver grains labeled MVBs (Fig. 1C),
ruling out significant contamination by these and other postsyn-
aptic elements. These data confirm that synaptosomal fraction-
ation measures the content of anterogradely transported 125I-
NT-3 in retinotectal terminals.
125I-NT-3 in presynaptic terminals in situ: quantitative
electron microscopy
To verify the amount of 125I-NT-3 in the presynaptic retinotectal
terminals in situ, quantitative autoradiography was performed at
the ultrastructural level. Typical examples of silver grains over
presynaptic and postsynaptic profiles are shown in Figure 1D–F.
A total of 530 silver grains from two chick tecta were sampled
randomly, and their location was analyzed at a magnification of
24,400. In many (42.5%) but not all of the labeled terminals,
LDCVs were visible in close vicinity (within 100 nm) of the
silver grains (Fig. 1E), consistent with the notion that antero-
grade neurotrophins localize in LDCVs (Fawcett et al., 1997;
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Michael et al., 1997; Holstege et al., 1999). The percentage of
silver grains over presynaptic terminals was 5.48% (range, 4.72–
6.17%) of the total 530 grains, and 3.15% were over postsynaptic
terminals (Fig. 1E,F). The percentage for presynaptic localiza-
tion of 125I-NT-3 (5.48%) is remarkably similar to that obtained
by synaptosomal fractionation (5.94%). Although we cannot rule
out coincidence, this similarity supports the validity of our assay
for the measurement of exogenous NT-3 in presynaptic axon
terminals.
125I-NT-3 in synaptosomes is intact by SDS-PAGE
At least some of the NT-3 that arrives in the tectum after
anterograde axonal transport from the eye is intact (von Bartheld
et al., 1996), but it was not known whether this included the
125I-NT-3 within synaptosomes. Protein extracted from synapto-
somal fractions was examined by SDS-PAGE. The large majority
of 125I-NT-3 recovered from synaptosomes was intact compared
with native 125I-NT-3 (Fig. 2A). When treated with detergents
and trypsin, a major fraction of NT-3 in the synaptosomal frac-
tion was degraded, indicating that NT-3 was located within a
membrane-confined compartment (data not shown). These re-
sults indicate that anterogradely transported NT-3 within synap-
tosomes remains intact.
Direct release from synaptosomes using the
conventional assay
We attempted to measure release of anterogradely transported
125I-NT-3 directly from synaptosomes by using a conventional
static release protocol (Androutsellis-Theotokis et al., 1996), with
the modification that 125I-NT-3 was loaded into tectal synapto-
somes via anterograde transport from the retina in vivo. After
injections of 50–100 ng of 125I-NT-3 into the eye, 3–4 pg
(450–600 cpm) of 125I-NT-3 was present in the synaptosomal
fraction, but only a fraction of this amount (1 pg 100–200
cpm) was recovered per tectum after washes, resuspension, and
warming to 37°C. The radioactivity in the supernatant after
Figure 1. Quantification of radiolabeled NT-3 in retinotectal terminals after anterograde axonal transport. A, Quantification of 125I-NT-3 in the
synaptosomal peak after centrifugation on ficoll-sucrose gradients and fractionation. The synaptosomal peak (SY) and the general membrane fraction
(GM) are indicated. B, Synaptosome shows a silver grain (arrowhead) next to a large dense core vesicle (arrow). C, Quantification of silver grains over
synaptosomes shows majority of grains over synaptosomes. Silver grains (n  94) were randomly analyzed. D, Synapse before release of NT-3. Cluster
of silver grains over a presynaptic terminal in layer f of the stratum griseum et fibrosum superficiale (SGFSf) of the optic tectum after anterograde
transport. Note the synaptic profile ( S). E, Synapse in the process of releasing NT-3. Silver grains over a presynaptic profile ( S) containing a large dense
core vesicle (arrow) and over a postsynaptic organelle reminiscent of a multivesicular body (arrowhead). F, Synapse after release of NT-3. Silver grain
on the postsynaptic side of the synapse ( S) overlying a multivesicular body (MVB). Scale bars, 200 nm.
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centrifugation ranged from 30 to 60%, and this amount was not
increased when synaptosomes were resuspended in high K
buffer instead of low K buffer (data not shown). The radioac-
tivity in the supernatant likely represents 125I-NT-3 that leaked
out of damaged immature synaptosomes, thus yielding a rela-
tively high and variable background that made it impossible to
measure secreted 125I-NT-3. The radioactivity levels in this prep
were approximately three orders of magnitude lower than what is
Figure 2. NT-3 in synaptosomes: K-induced-release of NT-3 and other proteins from axon terminals and binding of neurotrophins and neuropeptides
to synaptosomes. A, SDS gel shows that the large majority of NT-3 recovered from synaptosomes (Synapt.) migrates identically to native NT-3 at 14
kDa. The arrow indicates minor degradation products. Three month exposure. B, Plot of anterogradely transported 125I-NT-3 in the contralateral tectum
(cpm) as a function of the amount of 125I-NT-3 remaining in the injected eye. C, Plot of the 125I-NT-3 in the synaptosomal fraction from the contralateral
tectum (filled circles) as a function of the amount of 125I-NT-3 remaining in the injected eye. When the 125I-NT-3 in the eye was competed with 20–50-fold
excess cold NT-3, only background cpm were found in the synaptosomes (open circles). Note that the amounts of NT-3 in the tectum and in the
synaptosomal peak saturate at 10  10 6-15  10 6 cpm in the eye. D, Representative examples show decreased size of synaptosomal peaks (SY) from
tectum depolarized in high K buffer (right panel) compared with low K buffer (lef t panel). E, Quantification of D reveals a 15–20% decrease in NT-3
content in depolarized terminals (HiK, high K buffer; ***p  0.001, ANOVA, error bars indicate SEM). The average of the values for low K buffer
(LoK, 60 min) was taken as 100%. Comparison of incubation for 60 min versus 0 min in low K shows lack of basal (constitutive) release. Numbers of
experiments are indicated on bars. F, Release of radiolabeled tetanus toxin C fragment (Tet tox) was not statistically significant in high K buffer. G,
Radiolabeled cytochrome c (Cyt. C) was not released in high K buffer compared with low K buffer. H, Depolarized tecta showed a 25–50% release
of substance P (SP) from tectal terminals, measured by radioimmunoassay in 500 l samples (1:6 dilution). *p  0.05, t test, HiK versus LoK, 60 min,
error bars indicate SEM. I, When homogenized tecta were incubated with radiolabeled NT-3, NGF, or cytochrome c (Cyt C), NT-3 bound to tectal
terminals which was competed by excess cold NT-3, whereas NGF and cytochrome c showed very little binding. SY, Synaptosomal peak; GM, general
membrane fraction.
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usually used for synaptosomal release studies (Androutsellis-
Theotokis et al., 1996), and it was impossible to increase the
amount of anterogradely transported 125I-NT-3 per tectum, be-
cause its transport into synapses saturated at 10  10 6 cpm/eye
(Fig. 2B,C). We conclude that the measurement of anterogradely
transported 125I-NT-3 release directly from synaptosomes is im-
possible with the conventional technique.
Depolarization of tectal terminals induces release
of NT-3
Next we tested whether release of NT-3 from terminals in intact
tissue can be measured by quantifying the amount remaining
within terminals rather than measuring the amount that is re-
leased. Tecta whose retinotectal terminals had been loaded with
anterogradely transported 125I-NT-3 were incubated in oxygen-
ated buffer containing high K (56 mM), whereas control tecta
were incubated in low K (5 mM), and the amount of 125I-NT-3
remaining in terminals was quantified by measuring the amount
in the synaptosomal fraction relative to the total amount in the
tectum or the total amount in the ficoll–sucrose gradient tube.
Depolarization resulted in smaller synaptosomal peaks of 125I-
NT-3 (Fig. 2D), equivalent to a loss of 15–20% of the radioac-
tivity in the terminals after depolarization ( p  0.001; ANOVA;
multiple comparisons). These data were normalized to the total
amount of radioactivity in the gradient ultracentrifugation tube.
With an input of 40–80 ng of 125I-NT-3 in the eye, we found that
8000–12,000 cpm was transported to the tectum, and 6% (500
cpm) of this amount was reliably measured in the synaptosomal
peak (Table 1). No basal release of NT-3 was detected during the
60 min incubation step in low K buffer (Fig. 2E). To determine
whether the release of 125I-NT-3 was specific or merely reflected
the loss of 10–15% of presynaptic protein attributable to stimu-
lated release, the total protein content of synaptosomal prepara-
tions was compared between depolarized and control tecta.
There was no significant difference between the two groups (data
not shown), indicating that NT-3 was specifically released. These
data show that the novel release assay has significant advantages
over the conventional assay in terms of recovery, reliability, and
sensitivity, primarily because the synaptosomes are used merely
to determine the amount of radiolabeled NT-3. Because the
release has occurred in primarily intact tissue (the tectum), the
assay does not require the synaptosomes to be functionally intact,
which is a major challenge for immature synaptosomes prone to
leakage at 37°C.
Control experiments with other transported proteins:
limitations of the new assay
To determine whether the release of 125I-NT-3 was specific or
whether other proteins were released similarly when measured
with the same assay, we compared the transport, synaptic accu-
mulation, and release of NT-3, NGF, tetanus toxin, and cyto-
chrome c. The novel assay requires that the protein is retained in
the eye (to be internalized by retinal ganglion cells), that it be
transported to the terminals in the tectum with sufficient effi-
ciency, and that it accumulate in the retinotectal terminals. The
data showing how these three requirements are met for five
different proteins are summarized in Table 1. Cytochrome c
showed the highest retention in the eye (47%) after 20 hr, and
HSP showed the lowest (2%). The transport efficiencies of NT-3,
NGF, and cytochrome c were similar (1–2 pg/ng in the tectum
retained in the eye) and was significantly more efficient for teta-
nus toxin (4 pg/ng in the eye). The greatest differences between
the proteins were found with synaptic accumulation: NT-3 accu-
mulated in terminals almost six times more than NGF, whereas
tetanus toxin and cytochrome c accumulated only slightly more
than NGF (Table 1). These data provide evidence for some
remarkable differences in the trafficking of these proteins in the
retinotectal system. When we attempted to determine release of
NGF in high K buffer, it turned out that the counts per minutes
amounts in the synaptosomal fractions were too low to be reliably
quantified (Table 1). Release of tetanus toxin could be quantified
in this system; although there was a trend for lower peaks with
depolarization, the difference did not reach statistical significance
(Fig. 2F). Release of 125I-cytochrome c could also be quantified,
and there was no release of this protein with high K buffer (Fig.
2G). NGF transport appeared to be more efficient than in a
previous study (von Bartheld et al., 1996), probably because here
we measured radioactivity exclusively in the tectum, and free
iodine and degradation products were not removed by dehydra-
tion of the tissue. Together, these data show that 125I-NT-3 is
specifically stored in retinotectal terminals, and this capacity
makes it possible to quantify release of NT-3, which is released
during depolarization, unlike other proteins that can also be
transported to retinotectal terminals but do not accumulate there.
Requirements and limitations of our novel release assay thus
include the following: (1) internalization by projection neurons;
(2) anterograde axonal transport; (3) accumulation of the trans-
ported protein in presynaptic terminals; and (4) release of the
protein from the terminal. The utility of this assay may be useful
for any protein and neuronal projection system in which sufficient
Table 1. Behavior of different proteins in the retinotectal system of the chick embryo
Protein kDa
Retention in eye
20 hr after
injection (%)
Transport efficiency
pg/tectum/ng/eye
Receptor-
mediated
transport?
(%)
Synaptic accumulation
(% of whole tectum)
Amount in
synaptosomal
fraction
(cpm)
NT-3 28 30.3  2.4 1.34 0.1 80 5.94  0.36 522  48.5
NGF 26 25.1  3.5 2.02 0.4 50a 1.15  0.10 69.9  1.4
Tet tox 47 36.5  6.9 4.04 0.6 80 1.72  0.16 170  35.5
Cyt. C 12.3 47.1  2.1 1.78 0.4 0b 2.06  0.27 162  23.2
SP 1.3 1.8  0.30 0.52 0.1 	10 0.58  0.11 27  2.6
Retention in the eye, efficiencies of anterograde axonal transport, and accumulation in retinotectal synapses. Values are  SEM. Kilodaltons are indicated for monomers (Tet
tox, Cyt. C, and SP) and dimers (NT-3 and NGF). Tet tox, Tetanus toxin C fragment; Cyt. C, cytochrome C; SP, substance p.
aData from von Bartheld et al., 1996.
bData from Butowt and von Bartheld, 2001.
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amounts of protein can be quantified, and the novel assay thus
may not be restricted to NT-3 and the retinotectal system of chick
embryos.
Control experiments with substance P
A fraction of retinotectal projections in chicken use SP as a
neurotransmitter (Yamagata and Sanes, 1995), and release of SP
from synaptosomes can be induced by treatment with high K
(Lembeck et al., 1977). Radiolabeled SP was very poorly trans-
ported anterogradely by RGCs after injection in the eye (Table
1), presumably attributable to the lack of SP receptors on RGCs
that transport endogenous SP, and therefore it was not possible to
measure release of (exogenous) SP from retinotectal terminals.
To determine whether depolarization of tecta induces release of
endogenous SP from tectal terminals, similar to that of antero-
gradely transported NT-3, synaptosomal fractions were prepared
from 125I-NT-3-loaded tecta (to identify the synaptosomal
peaks), and the amount of SP in the synaptosomal peak after
depolarization (or maintenance of tecta in low K buffer as
controls) was measured by radioimmunoassay (Chen et al., 1996).
Approximately 25–50% of SP was released by depolarization
(Fig. 2H), which is similar to amounts of other neuropeptides
released from synaptosomes (25%) (Verhage et al., 1991b). These
data confirm the validity of our release protocol by comparison
with a classical neuropeptide.
Control experiments with added neurotrophins or
cytochrome c
Release of neuropeptides exclusively from terminals is conven-
tionally examined by measuring the release from synaptosomes
(Androutsellis-Theotokis et al., 1996) rather than examining the
release in intact tissue and then preparing synaptosomes to mea-
sure the amount remaining. To determine whether neurotrophins
and other small peptides bind to synaptosomes prepared from
E17 chick tecta, homogenized tecta were incubated for 15–20 min
with radiolabeled neurotrophins or radiolabeled cytochrome c,
and the tissue was processed as described. Significant amounts of
BDNF and NT-3 accumulated in the synaposomal peak, but very
little NGF or cytochrome c accumulated (Fig. 2 I). To test
whether binding of BDNF and NT-3 to synaptosomes was recep-
tor mediated, radiolabeled BDNF and NT-3 were incubated in
the presence of 500-fold excess cold same trophic factor. Much of
the BDNF (data not shown) and NT-3 (Fig. 2 I) bound to synap-
tosomes in a receptor-mediated manner. These data indicate that
NT-3 receptors [presumably tyrosine kinase receptor C (trkC)]
are present on tectal terminals (not necessarily retinotectal ter-
minals). These data also show that release of NT-3 from synap-
tosomes in a static release system likely would fail or grossly
underestimate release, because the released NT-3 would bind to
receptors present on synaptosomal membranes, thus confounding
the results.
Calcium dependence of NT-3 release
To determine whether the depolarization-induced release of
NT-3 required physiological concentrations of extracellular cal-
cium, 125I-NT-3-loaded tecta were incubated in calcium-free
buffer containing the calcium chelator BAPTA. High concentra-
tions of BAPTA (200 M) abolished the high K-induced release
of NT-3 (Fig. 3A), whereas lower concentrations (20 M) did not
(Table 2), indicating that the lower concentration of BAPTA was
not sufficient to chelate the calcium that may leak from the
dissected tecta into the buffer (volume of 3 ml). To determine
whether this was indeed the case, calcium was measured in buffers
with and without tecta in four conditions (0 M, 20 M, and 200
M BAPTA and 10 M BAPTA AM) in calcium-free buffers and
in addition in normal calcium buffers as shown in Table 2. Cal-
cium leakage from tecta increased the calcium concentration in
calcium-free buffers from 3 to 6 M, and this increase was not
significantly attenuated by 20 M BAPTA. BAPTA at 200 M
reliably reduced the calcium concentration in these buffers to 	1
M calcium. BAPTA AM at 10 M did not reduce the extracel-
lular calcium concentration significantly. We will refer to the 2
mM calcium concentration as “normal calcium,” to the 2–10 M
calcium concentration as “low calcium,” and to buffers with  1
M calcium concentration as “calcium-free” buffers. It should be
noted that the effective calcium concentration at the nerve ter-
minals within the tectum likely differs from the calcium concen-
tration that was measured in the incubation buffer.
To examine whether functional voltage-gated calcium channels
were required for depolarization-induced NT-3 release, tecta
were incubated in normal calcium buffer containing 100 M
cadmium chloride, a nonselective blocker of voltage-gated Ca2
channels. Cadmium significantly reduced the K-evoked NT-3
release (Fig. 3A). To determine whether functional N-type cal-
cium channels were required for NT-3 release, tecta were incu-
bated in buffer containing 0.1 M -conotoxin, an N-type Ca2
channel blocker. -Conotoxin significantly reduced NT-3 release
(Fig. 3A), consistent with the localization of N-type calcium
channels on presynaptic terminals (Westenbroek et al., 1992).
Nifedipine (10 M), a blocker of L-type Ca2 channels, showed
no significant effect on release (Fig. 3A). These data demonstrate
that high K-induced release of NT-3 depends on extracellular
calcium, which, during depolarization, enters the synapse via
N-type calcium channels.
Release of neurotrophins from brain slices and cultured neu-
rons depends on mobilization of calcium from intracellular stores
(Blo¨chl and Thoenen, 1995; Thoenen, 1995; Griesbeck et al.,
1999). To test whether NT-3 release from axon terminals also
required intracellular calcium release, tecta were incubated in low
calcium buffer containing the membrane-permeable calcium che-
lator BAPTA AM at 10 M (calcium concentrations of 4–6 M)
(Table 2). BAPTA AM effectively chelates calcium only after
membrane penetration, cleavage by intracellular esterases, and
intracellular accumulation (Tsien, 1981). The amount of extra-
cellular calcium (4–6 M) remaining in the BAPTA AM-treated
solution would have been sufficient to allow for the release of
NT-3 (compare with 20 M BAPTA in Table 2). Addition of the
relatively small amount of 10 M BAPTA AM significantly at-
tenuated the release of NT-3 (Fig. 3A). To verify that mobiliza-
tion of calcium from intracellular stores affects NT-3 release,
three experiments were performed. Dantrolene, an inhibitor of
calcium release from caffeine-sensitive intracellular stores (Blo¨chl
and Thoenen, 1995), was used at 50 M in both low calcium and
normal calcium high K buffer to determine whether it would
prevent the release of NT-3. In both low calcium and in normal
calcium buffer (as defined in Table 2), dantrolene completely
prevented the release of NT-3 (data shown for low calcium in Fig.
3A). These experiments indicate that high K-induced NT-3
release requires the release of calcium from intracellular stores
(calcium-induced calcium release). The role of intracellular cal-
cium was further tested by incubation in 1 mM 4-aminopyridine
(4-AP) in normal calcium buffer, which increases intracellular
(cytosolic) calcium and has been suggested to cause the release of
trophic factors (Grimaldi et al., 2001). 4-AP caused significant
NT-3 release (Fig. 3A). Finally, to verify that mobilization of
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calcium from intracellular stores and subsequent increase in in-
tracellular calcium is sufficient to induce release of NT-3, tecta
loaded with 125I-NT-3 were incubated in high K buffer contain-
ing 5 M thapsigargin. Thapsigargin induced a greater release of
NT-3 than depolarization alone (Fig. 3A). When thapsigargin was
tested in low K buffer, the evoked NT-3 release was of a similar
magnitude as seen with thapsigargin in high K buffer (Fig. 3A).
It should be noted that thapsigargin acutely induces a transient
calcium spike by mobilizing calcium from intracellular stores.
This acute effect is distinct from the chronic effects of thapsigar-
gin because of the depletion of intracellular calcium stores that
can be seen in dynamic (superfusion) release assays. Such long-
term effects of thapsigargin would not be seen in our release
assay, because NT-3 is not replenished as shown by colchicine
experiments (see below). Such considerations have to be kept in
mind when interpreting data obtained with our novel release
assay. To verify that the mobilization of calcium from intracellu-
lar stores by thapsigargin is immediate and does not require 60
min of incubation, we tested whether NT-3 was released within
	10 min incubation. As expected, the effect of thapsigargin on
NT-3 release was virtually identical within 10 min (data not
shown) and 60 min. Together, these data indicate that mobiliza-
tion of calcium from intracellular stores is sufficient to trigger
release of NT-3 from terminals.
Role of cAMP and CaM kinase II
cAMP has been implicated in the regulation of release of trans-
mitters and neurotrophins (Edwards et al., 1988; Thoenen, 1995;
Goodman et al., 1996). To determine whether cAMP is involved
in NT-3 release, we used the cAMP analog 8-Br-cAMP and
forskolin. Tecta were incubated in low K buffer containing 50
M 8-Br-cAMP. This drug induced NT-3 release (Fig. 3B), con-
sistent with the notion that cAMP is involved in the release
mechanism. NT-3 release was also induced by 10 M forskolin, an
adenylate cyclase activator (Fig. 3B). Thus, two distinct ways to
elevate cAMP levels showed the same result, namely release of
NT-3, further supporting the notion that cAMP indeed is in-
volved in the regulation of NT-3 release. Protein kinases regulate
synaptic transmission, with the most direct evidence for Ca2/
calmodulin-dependent protein kinase II (CaM kinase II) (Llinas
Figure 3. Manipulation of NT-3 release from axon terminals
by modulation of calcium, other ions, or second messengers. A,
High K-induced release of NT-3 was abolished by BAPTA
(BAP), BAPTA/AM (B/AM), cadmium chloride (CAD),
-conotoxin GVIA (CON), dantrolene (DAN), but not nifed-
ipine (NIF). Release of NT-3 was elicited by thapsigargin
(THA), both in high and low K, and to a lesser extent by
4-aminopyridine (4AP). B, Release of NT-3 was induced by
8-bromo-cAMP (8BR) or forskolin (FOR). High K-induced
release of NT-3 was reduced by the CaM kinase II inhibitor
KN-93 (KN93), but not by the inactive analog KN-92 (KN92).
Replacing extracellular sodium with N-methyl glucamine
(NMG) significantly reduced release of NT-3 induced by high
K. High K-induced release of NT-3 was unaffected by
tetrodotoxin (TTX) treatment. The Na/K ATPase inhibitor
strophanthidin (STR) induced release in low K buffer. The
number of independent experiments is indicated on bars. Error
bars indicate SEM. All experimental data points were cali-
brated in the same batch by obtaining control data without the
pharmacological agent. r., release; n.r., no release. Statistical
significance compared with LoK (•) or HiK (*) was deter-
mined by ANOVA with p  0.05 (* or •), p  0.01 (** or ••),
and p  0.001 (*** or •••).
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et al., 1991; Kelly, 1993). To test whether CaM kinase II affects
NT-3 release, we used the selective inhibitor, KN-93, at doses
which primarily abolish the activity of CaM kinase II, but not of
other kinases (10 M) (Sumi et al., 1991). As a control, we used
the inactive analog, KN-92 (10 M). KN-93 significantly reduced
high K-induced NT-3 release, whereas KN-92 had no effect
(Fig. 3B). These data indicate that cAMP and CaM kinase II may
act downstream of the depolarization induced by high K.
Role of extracellular sodium
The role of extracellular sodium for the release of neurotrophins
is controversial. Initial studies on the release of neurotrophins
concluded that extracellular sodium is required for regulated
release of neurotrophins from dendritic and somal compartments
(Blo¨chl and Thoenen, 1995), but this may have been attributable
to an independent blocking effect of the sodium substitute,
N-methyl-D-glucamine (NMG) (Hoener, 2000). Release of neu-
ropeptides from terminals (rather than whole cells) does seem to
require sodium influx (Stuenkel and Nordmann, 1993; Thirion et
al., 1999). To determine whether low extracellular sodium may
attenuate NT-3 release from axon terminals, 125I-NT-3 loaded
tecta were incubated in buffer containing high K, and NMG to
replace  90% of the extracellular sodium. As seen in Figure 3B,
replacement of sodium reduced the release of NT-3. When NMG
was washed out and the buffer replaced with normal sodium, high
K buffer induced NT-3 release (data not shown), indicating that
the effect of NMG was reversible. To determine whether the
opposite treatment, increased influx of sodium rather than de-
creased influx as with NMG, will have the opposite effect on NT-3
release, we used strophanthidin, a sodium-potassium ATPase
inhibitor (Meyer and Cooper, 1981). As expected, incubation of
tecta with 500 M strophanthidin induced release of NT-3 (Fig.
3B). Release was not attenuated by incubation with tetrodotoxin
(TTX, 3 M) (Fig. 3B), indicating that TTX-sensitive sodium
channels are not required for the release process when induced by
high K. Together, these results may suggest that an unconven-
tional sodium-dependence of neurotrophin release may be a
general feature for neuropeptide release from axon terminals
(Stuenkel and Nordmann, 1993; Thirion et al., 1999).
Structural proteins involved in NT-3 release
Microtubules and microfilaments have been implicated in the
movement of vesicles from the axon shaft to the membrane at
nerve terminals for exocytosis (Westrum et al., 1983; Hirokawa et
al., 1989; Ashton and Dolly, 1991). Microfilaments are thought to
act as a barrier to small synaptic vesicle (SSV) fusion, but they
may aid in the translocation of LDCVs (Doussau and Augustine,
2000) and LDCVs are known to concentrate outside the active
zone (Verhage et al., 1991a). To determine whether microfila-
ments are required for NT-3 release, tecta were incubated with
0.2 M cytochalasin D. This drug significantly reduced NT-3
release (Fig. 4A). Microtubules are present in tectal nerve termi-
nals (Bird, 1989). To determine whether intact microtubules are
required for evoked NT-3 release, 125I-NT-3 loaded tecta were
incubated in high K buffer containing 175 M colchicine. Col-
chicine abolished the release of NT-3 (Fig. 4A), indicating that
intact microtubules are necessary for evoked NT-3 release from
axon terminals. The colchicine experiments also show that there
is no significant replenishment of NT-3 from axons into terminals
during the 60 min release period. If the released NT-3 was rapidly
replenished by anterograde flow from the axon, one would not
expect a net loss of NT-3 in terminals. Because colchicine blocks
all anterograde axonal transport of NT-3 (von Bartheld et al.,
1996), we can exclude this possibility.
Role of synaptobrevin/synaptobrevin analogs in
NT-3 release
Synaptobrevin and synaptobrevin analogs are required for re-
lease of neurotrophins from cell bodies and/or dendrites (Blo¨chl,
1998). Synaptobrevin can be cleaved by tetanus toxin (Schiavo et
al., 2000). To determine whether tetanus toxin treatment affects
NT-3 release from terminals, tecta were pretreated by intraocular
injection of the whole tetanus toxin (1–2 g) which is subse-
quently transported anterogradely to the retinotectal terminals
(Manning et al., 1990). To verify this mode of drug delivery, 300
ng of radiolabeled tetanus toxin C-fragment was injected into the
eye of chick embryos. Within 24–48 hr, 1 ng of the toxin accu-
mulated in the retinotectal axons and terminals (Fig. 4B). Sub-
sequent anterograde transport of 125I-NT-3 to the tectum was not
affected by intraocular injection of 1–2 g tetanus toxin (Fig. 4C).
Tetanus toxin in the retinotectal terminals (estimated 5 ng/tec-
tum) reduced the release of NT-3 from tectal terminals (Fig. 4A).
This suggests that intact synaptobrevin (or synaptobrevin ana-
logs) are required for the release of NT-3 from axon terminals,
Table 2. Calcium concentrations in incubation buffers with ( tect) and without ( tect) a chick optic tectum as a function of the concentration of
the calcium chelator BAPTA and resulting release of NT-3 from retinotectal terminals
Chelator
No Ca2 added to high K buffer Normal Ca2
0 M BAPTA 20 M BAPTA 200 M BAPTA 10 M BAPTA AM 0 M BAPTA
Condition  tect  tect  tect  tect  tect  tect  tect  tect  tect  tect
[Ca2] in M 3.32 6.91 2.63 4.29 0.55 0.77 4.18 5.64 2550 2760
SEM 0.30 0.75 0.44 0.95 0.073 0.067 0.15 1.28 40 125
p value p  0.21
(vs 0 BAPTA)
p  0.04
(vs 20 BAPTA)
p  0.51
(vs 20 BAPTA)
Designation Low calcium Low calcium Calcium-free Low calcium Normal calcium
NT-3 release (%) N/A 16.68 1.84 3.54 16.85
SEM N/A 3.53 2.02 2.86 2.26
p value p  0.05
(vs high K,
normal Ca)
p  0.01
(vs high K,
normal Ca)
p  0.05
(vs high K,
normal Ca)
p  0.001
(vs low K,
normal Ca)
All data are the mean from three to eight determinations with SEM. p values were calculated by unpaired t test.
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and that at least some of the release is accomplished by
synaptobrevin-mediated vesicle trafficking and/or exocytosis.
Requirements for the effect of thapsigargin on
NT-3 release
Are extracellular sodium, calcium, or intact microtubules re-
quired for the effect of thapsigargin? When tecta were cotreated
with NMG and thapsigargin, there was no significant reduction in
the amount of NT-3 that was released (Fig. 4D), indicating that
the effect of thapsigargin did not require extracellular sodium.
Thapsigargin did not require the influx of extracellular calcium
for triggering release, because incubation in calcium-free solution
containing 200 M BAPTA did not reduce the magnitude of
release (Fig. 4D). When colchicine treatment was combined with
thapsigargin, there was a significant reduction in the amount of
NT-3 that was released (Fig. 4D), indicating that colchicine may
act downstream of the mobilization of calcium from internal
stores. These data indicate that mobilization of calcium from
intracellular stores is sufficient to trigger NT-3 release, but re-
quires intact microtubules, presumably for vesicle translocation
(Doussau and Augustine, 2000).
Kainic acid induces NT-3 release in vivo
Kainic acid and tetrodotoxin increase and decrease, respectively,
the electrical activity of RGCs (Catsicas and Clarke, 1987; Karls-
son and Hallbo¨o¨k, 1998). To determine whether stimulation of
RGCs in vivo induces release of NT-3 similar to the depolariza-
tion of retinotectal terminals in vitro, 1 g kainic acid or PBS
vehicle control was injected in the eyes of chick embryos in ovo,
19 hr after intraocular injection of 125I-NT-3. The final concen-
tration of kainic acid in the eye ( 80 l volume) was estimated
to be 62 M. Animals were killed 45 min after the intraocular
injection of kainic acid, and their tecta were processed immedi-
ately for synaptosomal fractionation. Kainic acid induced the
release of 30% of the exogenous NT-3 present in the terminals
(Fig. 5). To determine whether this effect of kainic acid could be
blocked by treatment with tetrodotoxin (TTX), the eyes of em-
bryos were pretreated with TTX (0.16 g injected, final concen-
Figure 4. Manipulation of NT-3 release from axon terminals with toxins to structural proteins and examination of upstream and downstream events.
A, High K-induced release of NT-3 (HiK) was abolished by cytochalasin D (CYD), colchicine (COL), and pretreatment with tetanus toxin (TET).
Tetanus toxin was targeted specifically to retinotectal terminals by injection of 1 g of tetanus toxin in the eye 24 hr before NT-3 injection. B,
Autoradiography shows that radiolabeled tetanus toxin (125I-TET) was transported anterogradely by retinal ganglion cells to the optic tectum. Scale bar,
500 m. C, Anterograde transport of 125I-NT-3 was not reduced by doses of TET (1–2 g) in the eye that were used to target the toxin to retinotectal
terminals. CTL, control. D, Simultaneous treatment with N-methyl-glucamine (NMG) and thapsigargin (THA) did not reduce the amount of NT-3 that
was released, indicating that sodium influx may be upstream of THA action. Cotreatment with BAPTA (BAP) in calcium-free buffer did not attenuate
NT-3 release. Simultaneous treatment with colchicine (COL) and THA significantly reduced the release of NT-3, indicating that COL was acting
downstream of THA. The number of independent experiments is indicated on each bar. Error bars indicate SEM. Statistical significance compared with
LoK (•), HiK (*) THA only (§, D) was determined by ANOVA with p  0.05 (*, §), p  0.01 (**), and p  0.001 (*** or •••).
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tration estimated at 6.25 M), 20 min before the injection of
kainic acid. TTX treatment abolished the effect of kainic acid
(Fig. 5B). These data confirm in an in vivo experiment the results
from our exposure to drugs by bath application of whole tecta.
Is NT-3 packaged in large dense core vesicles?
Our ultrastructural autoradiography localized 125I-NT-3 in the
vicinity of large dense core vesicles (LDCVs) (Fig. 1E), but the
resolution of the 125I-autoradiography was not sufficient for un-
ambiguous identification of the types of vesicles which contain
NT-3 in presynaptic terminals. Therefore, vesicles of different
sizes were purified by differential sedimentation in sucrose gra-
dients (Huttner et al., 1983; Han and Fischbach, 1999). Vesicle
purification showed that only the anterogradely transported 125I-
NT-3 accumulated in fractions known to contain LDCVs (Han
and Fischbach, 1999), but not the 125I-NT-3 that was incubated
with synaptosomes (Fig. 6A). After incubation, 125I-NT-3 was
marginally increased in fractions containing SSVs. Because the
LDCVs are heterogeneous in size and the fractions containing
LDCVs also contain endosomes, these data do not prove that the
anterogradely transported NT-3 is exclusively associated with
LDCVs, but our data are consistent with this notion. When the
superficial layer of the optic tectum of E17 chick embryos was
immunolabeled for endogenous NT-3 and examined at the elec-
tron microscopic level, immunolabel was detected in LDCVs
(Fig. 6B). We estimate that 25% of terminals in retinorecipient
layers of the tectum contained LDCVs, and 5–6% of such
terminals contained LDCVs with NT-3-like immunoreactivity.
No labeled LDCVs were detected when the primary antibody was
omitted (data not shown). If 125I-NT-3 was present in LDCVs
within retinal axons, one would expect to see silver grains over
LDCVs in the stratum opticum (SO) within the tectum. Indeed,
we found silver grains over and adjacent to dense-cored vesicles
within axons of the SO (Fig. 6C). Because of the relatively small
size of the LDCVs and the fact that many silver grains may
obscure them, we did not attempt to quantify the correlation of
silver grains and LDCVs. Taken together, these results further
support the idea that anterogradely transported neurotrophins
are packaged in LDCVs.
Figure 5. Kainic acid induced release of NT-3 from axon terminals in
vivo. Injection of kainic acid (K A) in the eye increased the amount of
NT-3 that was released from retinotectal terminals compared with PBS-
treated controls (PBS). The KA-induced release of NT-3 was prevented
by injection of tetrodotoxin (TTX) in the eye 15 min before KA injection
when compared with PBS injections as a control for TTX. The number of
independent experiments is indicated on each bar. Error bars indicate
SEM. Statistical significance compared with PBS (••) or the KAPBS
condition (§§) was determined by ANOVA with p  0.01 (••, §§).
Figure 6. Association of NT-3 with large dense core vesicles (LDCV)
rather than small synaptic vesicles (SSV) in retinotectal terminals. A, Ves-
icle purification of tecta containing anterogradely transported 125I-NT-3
shows higher levels of radioactivity in sedimentation fractions known to
contain LDCVs in chick embryo brains (Han and Fischbach, 1999), but not
in fractions known to contain SSVs (top panel). When homogenized tecta
were incubated with 125I-NT-3 (bottom panel), radioactivity was seen in
sedimentation fractions known to accumulate SSVs (Han and Fischbach,
1999). B, Section through a retinotectal terminal from a 17-d-old chick
embryo immunolabeled with an antibody to NT-3, processed with
horseradish-peroxidase, and visualized with diaminobenzidine. Note reac-
tion product in a large dense core vesicle (arrow). Scale bar, 100 nm. C,
Section through the stratum opticum (SO) of the optic tectum after injec-
tion of 125I-NT-3 in the eye. Note a cluster of silver grains in the vicinity of
a large dense core vesicle (arrow) in sectioned retinotectal fibers. Scale bar,
500 nm.
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DISCUSSION
Our study provides first direct evidence for mechanisms of re-
lease of anterogradely transported neurotrophins from axon ter-
minals. We found that NT-3 is released by depolarization, that
this release depends on intracellular and extracellular calcium,
and can be evoked by mobilization of calcium from intracellular
stores. Release is further regulated by cAMP and CaM kinase II.
We show that release occurs by exocytosis of presumptive large
dense-core vesicles (LDCVs). Anterogradely transported and
presynaptically located neurotrophins are released by changes in
local, intracellular calcium concentrations.
Technical considerations
Previous studies used immunological techniques to measure the
amounts of neurotrophins released from entire cells (cell bodies,
dendrites and axons) into medium or perfusate (Blo¨chl and
Thoenen, 1995; Goodman et al., 1996), but this technology was
not sufficiently sensitive to measure the excessively small amounts
(molecules per synapse) exclusively released from axon terminals.
Therefore, it is important to consider whether we accurately
measured the amount of 125I-NT-3 in retinotectal terminals by
synaptosomal fractionation and gamma counting. When synapto-
somal measurements were compared with quantitative analysis of
the in situ distribution of silver grains after autoradiography at the
ultrastructural level, the morphological and the biochemical /phar-
macological data showed a remarkable agreement for the esti-
mates of exogenous NT-3 in axon terminals (5.48% vs. 5.94%).
Another important issue is whether anterogradely transported
exogenous NT-3 is released by the same mechanisms as antero-
gradely transported endogenous NT-3. Do endogenous and exog-
enous neurotrophins pass through the same organelles? RGCs in
chicks express NT-3, and endogenous NT-3 is anterogradely
transported to the terminals in the optic tectum (von Bartheld and
Butowt, 2000). Proteins destined for anterograde transport have
to be processed in the Golgi system (Hammerschlag et al., 1982).
Exogenous NT-3 (but very little BDNF) accumulates in the Golgi
system of RGCs (Butowt and von Bartheld, 2001; von Bartheld et
al., 2001) and transcytoses RGCs in a receptor-mediated manner,
possibly by sequential binding to trkC and p75 receptors (Butowt
and von Bartheld, 2001). Therefore, it is likely that exogenous
NT-3 joins the pathway normally taken by endogenous NT-3.
Alternatively, there may be parallel pathways of release, one for
newly synthesized NT-3, and one for transcytosed NT-3 (von
Bartheld et al., 2001).
Our release assay has significant advantages (sensitivity and
synapse specificity) as well as limitations compared with conven-
tional release assays. It requires sufficient internalization, antero-
grade axonal transport, and accumulation of the protein in pre-
synaptic terminals, and it is not a dynamic assay with
replenishment of the source. Nevertheless, its utility is not nec-
essarily restricted to the retinotectal system or to neurotrophins.
Molecular determinants of NT-3 release
Our results discern 3 major steps that lead to the release of NT-3
from axon terminals (Fig. 7). These conclusions are based on data
obtained with a variety of pharmacological agents at concentra-
tions commonly used for tissue slices. The first step involves
depolarization of the axon terminus with influx of calcium
through N-type calcium channels. The second step may be in-
duced by calcium influx and/or mobilization of calcium from
intracellular stores. Increased calcium concentrations in the pre-
synaptic compartment (Verhage et al., 1991a), as well as kinase
activation (cyclic AMP-dependent kinases and CaM kinase II),
may provide signals for vesicle translocation via microtubules to
the active zone at the synaptic cleft. The vesicle then fuses with
the membrane, presumably mediated by synaptobrevin, because
release is tetanus-toxin-sensitive. The neurotrophin is released
and may diffuse in the synaptic cleft to bind to presynaptic and/or
postsynaptic neurotrophin receptors (Levine et al., 1995; Wu et
al., 1996; Kafitz et al., 1999; von Bartheld et al., 2001). The role of
sodium influx for neurotrophin release from whole cells is con-
troversial (Blo¨chl and Thoenen, 1995; Hoener, 2000). We find
that NT-3 release from terminals requires sodium influx, appar-
ently via TTX-insensitive sodium channels, consistent with re-
ports of TTX-insensitive, sodium-evoked release of neuropep-
tides from axon terminals (Stuenkel and Nordmann, 1993) and
sodium influx into docked vesicles (Thirion et al., 1999). Sodium
influx may also interact with mobilization of calcium from inter-
nal stores (Berridge, 1998).
Release from different compartments is regulated by
different mechanisms
Potassium-stimulated release of neuropeptides is typically medi-
ated by activation of L-type calcium channels (Trimble et al.,
1991; Meir et al., 1999), but release from terminals is often
mediated via N-type channels, consistent with their localization
in terminals (Westenbroek et al., 1992; Simmons et al., 1995). Our
study is the first to examine mechanisms of the release of antero-
gradely transported neurotrophins. Previous studies on the re-
lease of neurotrophins could not discriminate between different
compartments (dendrites, soma, and axons) (Blo¨chl and
Thoenen, 1995; Goodman et al., 1996; Blo¨chl, 1998; Griesbeck et
Figure 7. Diagram summarizes the proposed mechanisms of release of
anterogradely transported NT-3 from axon terminals. Depolarization by
high potassium (K) opens N-type calcium channels. Calcium influx
induces calcium release from internal stores. Increased intraterminal
calcium concentrations are sufficient to induce release of NT-3 containing
vesicles. Release can also be induced by cAMP and requires CaM kinase
II activity. Second messengers and kinases may act directly on vesicle
release or indirectly via calcium mobilization from internal stores (Hille
et al., 1999). Translocation of the NT-3-containing vesicle requires intact
microtubules and microfilaments, and fusion of the vesicle depends on
synaptobrevin or synaptobrevin-like molecules. Once released, NT-3 dif-
fuses across the synaptic cleft, binds to trkC receptors, is internalized, and
accumulates postsynaptically in multivesicular bodies (MVB).
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al., 1999), or the exogenous neurotrophin was loaded to uniden-
tified compartments within synaptosomes (Androutsellis-
Theotokis et al., 1996). The release from dendritic /somal com-
partments showed a constitutive and regulated release, with the
constitutive release primarily restricted to the soma and proximal
dendrites (Blo¨chl and Thoenen, 1995, 1996; Goodman et al.,
1996). In contrast, anterogradely transported NT-3 from retino-
tectal terminals was not released constitutively, or such release
was below the detection limit of our assay. Release of neurotro-
phins from cell bodies/dendrites was induced by mobilization of
calcium from intracellular stores, and appeared to require extra-
cellular calcium only when examined in a static release system,
but not in a perfusion release system (Griesbeck et al., 1999).
Release of NT-3 from axon terminals was regulated by intracel-
lular calcium, but was also triggered by influx of extracellular
calcium (present study) (Fig. 3), similar to the release of antero-
gradely transported IGF-I (Nieto-Bona et al., 1993). It is not clear
whether targeting and release differs between neurotrophins and
whether overexpression may change release mechanisms attrib-
utable to rate-limiting sorting steps (Mowla et al., 1999; Farhadi
et al., 2000), or whether all neurotrophins are processed and
released similarly (Blo¨chl and Thoenen, 1995; Goodman et al.,
1996; Heymach et al., 1996; Canossa et al., 1997; Griesbeck et al.,
1999).
Localization of anterogradely transported
neurotrophins in presynaptic organelles
Because of the low levels of expression and small number of
molecules which are anterogradely transported, it has been diffi-
cult to determine in which types of vesicles (if any) the antero-
gradely transported neurotrophins are packaged. BDNF has been
localized to LDCVs in terminals of the spinal cord (Michael et
al., 1997; Holstege et al., 1999) and to LDCV fractions of the
hippocampus after vesicle purification (Fawcett et al., 1997).
Anterogradely transported NT-3 did not accumulate within small
synaptic vesicles in retinotectal terminals, rather, our data indi-
cate that NT-3 was associated with LDCVs (Figs. 1E, 6A–C).
Thus, increasing evidence indicates that anterogradely trans-
ported neurotrophins are contained within LDCVs and are re-
leased by conventional exocytosis.
Amount of released exogenous NT-3 is a
few molecules/synapse
The amount of exogenous NT-3 that was transferred from a
presynaptic to a postsynaptic site in retinotectal terminals during
depolarization was calculated to be 1–1.2 pg. The number of
RGCs in the chick embryo at E16–17 is 2–3 million (Rager,
1980), the approximate average number of axon branches of
individual RGCs in the tectum is 20 at this age (Thanos and
Bonhoeffer, 1987), and thus the number of RGC terminals in the
tectum, and the number of released NT-3 molecules can be
estimated. On average, one RGC terminal released 0.5 mole-
cules 125I-NT-3, assuming that all RGCs transported NT-3 an-
terogradely, and that NT-3 was distributed among all RGC ter-
minals. This appears to be a small amount, but one molecule of
NT-3 in the synaptic cleft (1020200 nm3  40,000 nm3) is
equivalent to a concentration of 40 M. This concentration is 4
orders of magnitude higher than what is thought to be sufficient
for saturation of neurotrophin receptors. Thus, a small number of
molecules/synaptic cleft may be sufficient for activation of
postsynaptic trk receptors.
Implications of release mechanisms for an
understanding of synaptic plasticity
Neurotrophins also stimulate the release of neurotrophins
(Canossa et al., 1997; Kru¨ttgen et al., 1998). In the retinotectal
system, BDNF is expressed and upregulated by increased neural
activity (Karlsson and Hallbo¨o¨k, 1998). BDNF is internalized by
RGC axons and retrogradely transported from the tectum to the
retina (Herzog and von Bartheld, 1998). Besides a direct effect of
NT-3 on axon branching (Inoue and Sanes, 1997) and synapse
formation (Martinez et al., 1998), release of NT-3 from retino-
tectal presynaptic terminals may also trigger subsequent BDNF
release from postsynaptic tectal neurons, and thereby stabilize
functional synapses (Snider and Lichtman, 1996; Canossa et al.,
1997; Boulanger and Poo, 1999; Wang et al., 2000; Poo, 2001; von
Bartheld et al., 2001). Recent studies have shifted focus on the
source of neurotrophins in the synaptic cleft to include a presyn-
aptic release and a postsynaptic transfer of neurotrophins (Kafitz
et al., 1999; Poo, 2001; Lever et al., 2001). The technology
developed in the present report will help to elucidate the mech-
anisms of release of neurotrophins from axon terminals and help
to define their roles as extremely potent excitatory neurotrans-
mitters as well as neuromodulators in synaptic plasticity.
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